Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease

NCT ID: NCT00774969

Last Updated: 2008-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2008-04-30

Brief Summary

The purpose of this study is to evaluate the blood levels of Metronidazole after application to the peri anal area after a single dose and 6 or 7 days application.

Conditions

Perianal Crohns'

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE

Study Groups

All

6 patients with Perianal Crohn's Disease and 10 healthy Volunteers

Group Type: EXPERIMENTAL

Metronidazole

Intervention Type: DRUG

Metronidazole 10% ointment three times a day 7 days

Interventions

Metronidazole

Metronidazole 10% ointment three times a day 7 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patient group:

• Male and female patients with Crohn's disease (diagnosed by radiology, endoscopy and pathology), with anorectal involvement.
• Aged 18-65 years.
• Have had perianal symptoms for longer than 2 months
• Have a score of 5 or above in the Perianal Crohn's Disease Activity Index (PCDAI)
• Have a score of 1 or above on the 'Type of perianal disease' assessment of the PCDAI
• Subjects can be on concomitant medication. Acceptable regimens are:

• Aminosalicylates at a dosage that has been stable for more than 4 weeks before screening;Infliximab on a stable infusion regimen;
• Oral corticosteroids <40mg per day; Methotrexate, provided that dosage has been stable for more than 4 weeks; azathioprine or mercaptopurine at a dosage that has been stable for more than 8 weeks;
• Antibiotics at a dosage that has been stable for 4 weeks but excluding metronidazole.
• Cyclosporin on a stable dose for more than 4 weeks.
• If patients have setons these must have been in place for at least 4 weeks prior to screening.
• If female, the subject must not be lactating and must be (a) post-menopausal, (b) surgically sterilised, or (c) have a negative pregnancy test result prior to entry into the study and will use double-barrier methods of contraception (two separate methods of birth control, one of which may include oral contraception) for the duration of the study.
• Must have provided written informed consent to participate.

Healthy volunteer group:

• They have had surgery to the anus or rectum in the past 4 weeks.
• Have a history of inflammatory bowel disease.
• Allergic to metronidazole.
• Are taking any prohibited medication.
• Not prepared to refrain from drinking alcohol during the course of the study.
• Deemed mentally incompetent.
• Considered by their physician unlikely to be able to comply with the protocol.
• Has donated blood within the past 3 months.
• Taken part in an experimental drug study in the preceding three months.

Exclusion Criteria

Patient group:

• They have had surgery to the anus or rectum in the past 4 weeks.
• They have a perianal abscess requiring incision and drainage.
• They have a stoma of less than 6 months duration.
• Allergic to metronidazole.
• Are taking any prohibited medication.
• Not prepared to refrain from drinking alcohol during the course of the study.
• Deemed mentally incompetent.
• Considered by their physician unlikely to be able to comply with the protocol.
• Has donated blood within the past 3 months.
• Taken part in an experimental drug study in the preceding three months.
• Has donated blood within the past 3 months.
• Taken part in an experimental drug study in the preceding three months.

Healthy volunteer group:

• They have had surgery to the anus or rectum in the past 4 weeks.
• Have a history of inflammatory bowel disease.
• Allergic to metronidazole.
• Are taking any prohibited medication.
• Not prepared to refrain from drinking alcohol during the course of the study.
• Deemed mentally incompetent.
• Considered by their physician unlikely to be able to comply with the protocol.
• Has donated blood within the past 3 months.
• Taken part in an experimental drug study in the preceding three months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

S.L.A. Pharma AG

INDUSTRY

Sponsor Role: lead

Principal Investigators

Christopher J Jordan, BSC

Role: STUDY_DIRECTOR

SLA Pharma

Locations

Sainsbury Wing, St Marks & Northwick Park Hospitals, Watford Road

Harrow, , United Kingdom

Countries

United Kingdom

Other Identifiers

EudraCT/IND 2007003173-68

Identifier Type: -

Identifier Source: secondary_id

MET/PK/01

Identifier Type: -

Identifier Source: org_study_id